11
Participants
Start Date
August 1, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Combination Intervention
"1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4~2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12~3. MVA/HIV62B (MVA62B) boost at Week 20~4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)~5. ATI with single dose of VRC07 and 10-1074 at Week 34"
Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco
Collaborators (2)
amfAR, The Foundation for AIDS Research
OTHER
International AIDS Vaccine Initiative
NETWORK
Ichor Medical Systems Incorporated
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Rockefeller University
OTHER
Mologen AG
INDUSTRY
GeoVax, Inc.
INDUSTRY
University of California, San Francisco
OTHER